Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (UKALL14)

• ClinicalTrials.gov Identifier: NCT01085617
• Recruitment Status: Recruiting
• First Posted: March 12, 2010
• Last Update Posted: May 18, 2021
• Sponsor: University College, London
• Information provided by (Responsible Party): University College, London

Study Description

Brief Summary:

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. It is not yet known which regimen of combination chemotherapy given together with or without monoclonal antibodies is more effective in treating patients with newly diagnosed acute lymphoblastic leukemia.

PURPOSE: This randomized phase III trial is studying standard chemotherapy to see how well it works when given together with or without rituximab, and with or without nelarabine in treating patients with newly diagnosed acute lymphoblastic leukemia.

Condition or disease	Intervention/treatment	Phase
Leukemia; Mucositis; Oral Complications	Biological: palifermin; Biological: rituximab; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: fludarabine phosphate; Drug: imatinib mesylate; Drug: melphalan; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: vincristine sulfate; Procedure: allogeneic hematopoietic stem cell transplantation; Radiation: total-body irradiation	Phase 3

Detailed Description:

OBJECTIVES:

Primary

• To determine if the addition of a monoclonal antibody (none vs. rituximab) improves event-free survival (EFS) in patients with newly diagnosed precursor B-cell acute lymphoblastic leukemia (ALL).
• To determine if the addition of nelarabine improves outcome for patients with T-cell ALL.

Secondary

• To determine the tolerability of pegaspargase in induction therapy of all patients.
• To compare anti-asparaginase antibody levels in patients with B-lineage ALL.
• To determine whether risk-adapted introduction of unrelated donor hematopoietic stem cell transplantation (HSCT) (myeloablative conditioning in patients ≤ 40 years old and non-myeloablative conditioning in patients > 40 years old) results in greater EFS for patients at highest risk of relapse.
• To compare the efficacy of two schedules (standard vs collapsed) of palifermin in preventing severe mucosal toxicity in patients treated with etoposide, total-body irradiation, and HSCT-conditioning therapy.
• To assess the late effects of this treatment in these patients.
• To identify and describe some of the adverse physical and psychosocial consequences of this disease and its treatment.

OUTLINE: This is a multicenter study. There are 3 randomizations at different timepoints in the trial, each patient undergoes at least 1 but no more than 2 randomizations.

• Part 1 standard induction therapy (all patients*, weeks 1-4): Patients receive daunorubicin hydrochloride IV over 20 minutes and vincristine sulfate IV over 5-10 minutes on days 1, 8, 15, and 22; oral dexamethasone once a day on days 1-5, 8-11, and 15-18; pegaspargase IV over 1-2 hours on days 4 and 18; and methotrexate intrathecally (IT) on day 14.

NOTE: *Patients with Philadelphia-positive (Ph+) disease should also receive oral imatinib mesylate once a day on days 1-28.

• Randomized concurrent monoclonal antibody therapy (for patients with precursor B-cell acute lymphoblastic leukemia [ALL]): Patients with precursor B-cell ALL are randomized to 1 of 4 monoclonal antibody treatment arms (given concurrently with part 1 standard induction therapy):

  • Arm B1: Patients do not receive any monoclonal antibody therapy.

  • Arm B2 : Patients receive rituximab IV on days 3, 10, 17, and 24.

    • Part 2 standard induction therapy (all patients*, weeks 5-8): Patients receive cyclophosphamide IV over 30 minutes on days 1 and 15; cytarabine IV on days 2-5, 9-12, 16-19, and 23-26; oral mercaptopurine once a day on days 1-28; and methotrexate IT on days 1, 8, 15, and 22.

NOTE: *Patients with Ph+ disease should also receive oral imatinib mesylate once a day on days 1-30.

• Randomized subsequent nelarabine therapy (for Patients with T-cell ALL) Patients with T-cell ALL are randomized to 1 of 2 treatment arms, to be administered after completion of part 2 standard induction therapy.

  • Arm T1: Patients do not receive any other therapy during induction.

  • Arm T2: Patients receive nelarabine IV over 2 hours on days 1, 3, and 5. Patients who do not achieve complete remission (CR) after part 2 standard induction therapy are taken off study.

    • Intensification/central nervous system prophylaxis (patients not eligible for transplant OR patients > 40 years at study entry and eligible for transplant)*: Beginning after recovery from part 2 standard induction therapy, patients receive high-dose methotrexate IV on days 1 and 15 and pegaspargase IV over 1-2 hours on days 2 and 16.

NOTE: *Patients with Philadelphia-positive (Ph+) disease should also receive oral imatinib mesylate once a day on days 1-28.

Patients eligible for allogeneic hematopoietic stem cell transplantation (HSCT) (i.e., any patient with an HLA-compatible sibling donor or high risk patients with a molecularly matched donor) undergo transplantation; patients not eligible for HSCT undergo consolidation followed by maintenance therapy.

• Consolidation therapy* (patients not eligible for transplantation):

  • Course 1: Beginning after completion of intensification therapy, patients receive cytarabine IV and high-dose etoposide IV over 30 minutes on days 1-5, pegaspargase IV over 1-2 hours on day 5, and methotrexate IT on day 1. Patients proceed to course 2 beginning 3 weeks after the start of course 1 or when neutrophils recover.
  • Course 2: Patients receive cytarabine IV and high-dose etoposide IV over 30 minutes on days 1-5 and methotrexate IT on day 1. Patients proceed to course 3 beginning 3 weeks after the start of course 2 or when neutrophils recover.
  • Course 3 (delayed intensification): Patients receive daunorubicin hydrochloride IV over 20 minutes and vincristine sulfate IV over 5-10 minutes on days 1, 8, 15, and 22; pegaspargase IV over 1-2 hours on day 4; oral dexamethasone once a day on days 1-4, 8-11, 15-18, and 22-25; methotrexate IT on days 2 and 17; cyclophosphamide IV on day 29; cytarabine IV on days 30-33 and 37-40; and oral mercaptopurine once a day on days 29-42. Patients proceed to course 4 after neutrophils recover.
  • Course 4: Patients receive cytarabine IV, high-dose etoposide IV, and methotrexate IT as in course 2.

NOTE: *Patients with Ph+ disease should also receive oral imatinib mesylate once a day on days 1-7 in courses 1 and 2, on days 2-42 in course 3, and on days 1-8 in course 4.

• Maintenance therapy (patients not eligible for transplantation): Patients receive vincristine sulfate IV every 3 months, oral prednisolone once a day on days 1-5 every 3 months, oral mercaptopurine once daily, methotrexate IV or orally once a week, and methotrexate IT every 3 months for 2 years.

• Transplant conditioning and allogeneic HSCT:

  • Myeloablative-conditioning and allogeneic HSCT (patients ≤ 40 years old at study entry): Patients undergo total-body irradiation on days -7 to -4 and receive high-dose etoposide IV over 4 hours on day -3 or high-dose cyclophosphamide IV over 2 hours on days -3 and -2. Patients then undergo allogeneic HSCT on day 0.

Patients are stratified according to gender, donor (sibling donor vs. matched unrelated donor), and cellular type of ALL (precursor B-lineage vs. T-lineage). Patients are randomized to receive 1 of 2 palifermin treatment arms.

• Arm P1 (standard dose): Patients receive palifermin IV on days -3 to 2.

• Arm P2 (collapsed dose): Patients receive palifermin IV on days -1 to 2.

  • Non-myeloablative-conditioning and allogeneic HSCT (patients > 40 years old at study entry): Patients receive fludarabine phosphate IV over 30-60 minutes on days -7 to -3 and melphalan IV over 90 days on day -1. Recipients of unrelated donor HSCT also receive alemtuzumab IV over 2 hours on day -2 and -1; recipients of sibling HSCT receive alemtuzumab IV over 2 hours on day -1. Patients then undergo allogeneic HSCT on day 0. Patients also receive post transplant methotrexate IT every 3 months for 2 years.

Patients undergo blood and bone marrow sample collection periodically for correlative studies.

After completion of study treatment, patients are followed annually.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 811 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Randomised phase III trial of standard treatment +/- rituximab for patients with precursor B-cell ALL or nelarabine for patients with T-cell ALL. A further randomisation investigated two schedules of palifermin administration in patients undergoing myeloablative transplant.
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Randomized Trial for Adults With Newly Diagnosed Acute Lymphoblastic Leukemia
• Actual Study Start Date: December 2010
• Estimated Primary Completion Date: December 2022
• Estimated Study Completion Date: July 2023

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: B1 - Standard therapy; Standard chemotherapy for precursor B-cell ALL	Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: fludarabine phosphate; Drug: imatinib mesylate; Drug: melphalan; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: vincristine sulfate
Experimental: B2 - Rituximab; Standard chemotherapy for precursor B-cell ALL plus weekly rituximab infusions during phase 1 induction	Biological: rituximab; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: fludarabine phosphate; Drug: imatinib mesylate; Drug: melphalan; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: vincristine sulfate
Active Comparator: T1 - Standard therapy; Standard chemotherapy for T-cell ALL	Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: fludarabine phosphate; Drug: melphalan; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: vincristine sulfate
Experimental: T2 - Nelarabine; Standard chemotherapy for T-cell ALL plus an additional course of treatment with nelarabine following phase 2 induction	Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: fludarabine phosphate; Drug: melphalan; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: vincristine sulfate
Active Comparator: P1 - standard palifermin; 6 doses of palifermin before/after myeloablative stem cell transplant (randomisation closed due to lack of clinical relevance in 2016)	Biological: palifermin; Procedure: allogeneic hematopoietic stem cell transplantation; Radiation: total-body irradiation
Experimental: P2 - collapsed palifermin; 1 x large dose of palifermin before myeloablative stem cell transplant and 3 low doses after transplant (randomisation closed due to lack of clinical relevance in 2016)	Biological: palifermin; Procedure: allogeneic hematopoietic stem cell transplantation; Radiation: total-body irradiation

Outcome Measures

Primary Outcome Measures :

1. Event-free survival [ Time Frame: 3 years ]
   Time from randomisation to relapse or death from any cause

Secondary Outcome Measures :

1. Anti-asparaginase antibodies in patients treated with monoclonal antibody therapy [ Time Frame: Throughout treatment ]
   Antibody levels in sequential samples during pegylated asparaginase treatment
2. Overall survival [ Time Frame: 3 years ]
   Time from randomisation to death from any cause
3. Complete remission (CR) rate [ Time Frame: Throughout treatment ]
   Proportion of patients achieving morphological complete remission
4. Minimal-residual disease quantification after first phase of induction and post-transplantation [ Time Frame: Throughout treatment ]
   Minimal residual disease measured at central laboratory after phase 1 induction and post transplant
5. Relapse rate (including bone marrow and CNS relapse) [ Time Frame: 3 years ]
   Proportion of patients experiencing a bone marrow of CNS relapse after entering complete remission
6. Death in CR [ Time Frame: 3 years ]
   Proportion of patients dying while their ALL is in complete remission
7. Toxicity related to pegaspargase [ Time Frame: Throughout treatment ]
   Rates of hypersensitivity, changes to Erwinia, or withdrawal of asparaginase treatment
8. Mucositis score in patients treated with palifermin [ Time Frame: 30 days ]
   OMQD score, number of doses of methotrexate given, acute GVHD rates

Eligibility Criteria

• Ages Eligible for Study: 25 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

DISEASE CHARACTERISTICS:

• Newly diagnosed, previously untreated acute lymphoblastic leukemia

  • A pre-phase steroid treatment of 5-7 days is required and can be started prior to registration
• Philadelphia chromosome-negative or -positive patients are eligible
• No blast transformation of chronic myeloid leukemia
• No mature B-cell leukemia [i.e., Burkitt disease t(8,14)(q24 ;q32)] or variant c-myc translocations [e.g., t(2;8)(p12;q24), t(8;22)(q24;q11)]

• Patients who undergo study transplantation must have HLA-compatible sibling or unrelated donor

  • 8/8 molecular match at -A, -B, -C, and -DR (DQ mismatch is permitted)

• Patients meeting ≥ 1 the following criteria are considered high-risk:

  • Over 40 years old
  • WBC ≥ 30 x 10^9/L (precursor-B) OR ≥ 100 x 10^9/L (T-lineage)

  • Any 1 or more of the following cytogenetic abnormalities:

    • t(4;11)(q21;q23)/MLL-AF4
    • Low hypodiploidy/near triploidy (30-39 chromosomes/60-78 chromosomes)
    • Complex karyotype (≥ 5 chromosomal abnormalities)
    • Philadelphia chromosome t(9;22) (q34;q11)/BCR-ABL1 (detected by cytogenetic or molecular methods)
  • High-risk minimal-residual disease after completion of part 2 standard induction therapy

PATIENT CHARACTERISTICS:

• No known HIV infection
• Not pregnant or nursing (no nursing during and for 12 months after completion of study therapy)
• Negative pregnancy test
• Fertile patients must use effective contraception during and for up to 12 months after completion of study therapy

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

Contacts and Locations

Locations

United Kingdom

UCL Cancer Institute; Recruiting

London, England, United Kingdom, WC1E 6DD

Contact: Contact Person 44-207-830-2833

Sponsors and Collaborators

University College, London

Investigators

• Principal Investigator: Adele K. Fielding; University College London (UCL) Cancer Institute

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Marks DI, Clifton-Hadley L, Copland M, Hussain J, Menne TF, McMillan A, Moorman AV, Morley N, Okasha D, Patel B, Patrick P, Potter MN, Rowntree CJ, Kirkwood AA, Fielding AK. In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial. Lancet Haematol. 2022 Apr;9(4):e276-e288. doi: 10.1016/S2352-3026(22)00036-9.

Marks DI, Kirkwood AA, Rowntree CJ, Aguiar M, Bailey KE, Beaton B, Cahalin P, Castleton AZ, Clifton-Hadley L, Copland M, Goldstone AH, Kelly R, Lawrie E, Lee S, McMillan AK, McMullin MF, Menne TF, Mitchell RJ, Moorman AV, Patel B, Patrick P, Smith P, Taussig D, Yallop D, Alapi KZ, Fielding AK. Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial. Lancet Haematol. 2022 Apr;9(4):e262-e275. doi: 10.1016/S2352-3026(22)00038-2.

Mitchell RJ, Kirkwood AA, Barretta E, Clifton-Hadley L, Lawrie E, Lee S, Leongamornlert D, Marks DI, McMillan AK, Menne TF, Papaemmanuil E, Patel B, Patrick P, Rowntree CJ, Zareian N, Alapi KZ, Moorman AV, Fielding AK. IKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial. Blood Adv. 2021 Sep 14;5(17):3322-3332. doi: 10.1182/bloodadvances.2021004430.

Patel B, Kirkwood AA, Dey A, Marks DI, McMillan AK, Menne TF, Micklewright L, Patrick P, Purnell S, Rowntree CJ, Smith P, Fielding AK. Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial. Leukemia. 2017 Jan;31(1):58-64. doi: 10.1038/leu.2016.219. Epub 2016 Aug 2.

• Responsible Party: University College, London
• ClinicalTrials.gov Identifier: NCT01085617
• Other Study ID Numbers: CDR0000667211; UCL-08-0167 ( Other Identifier: UCL ); EU-21009 ( Other Identifier: NK ); 2009-012717-22 ( EudraCT Number ); UCL-UKALL14 ( Other Identifier: UCL ); MREC-09-H0711-90 ( Other Identifier: Research Ethics Committee ); NCRI-UCL-08-0167 ( Other Identifier: NK ); CRUK-C27995-A9609 ( Other Grant/Funding Number: Cancer Research UK )
• First Posted: March 12, 2010
• Last Update Posted: May 18, 2021
• Last Verified: May 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University College, London:

oral complications; mucositis; untreated adult acute lymphoblastic leukemia; B-cell adult acute lymphoblastic leukemia; T-cell adult acute lymphoblastic leukemia; Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia

Additional relevant MeSH terms:

Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphoid; Mucositis; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Mouth Diseases; Stomatognathic Diseases; Cytarabine; Cyclophosphamide; Melphalan; Rituximab; Methotrexate; Fludarabine; Fludarabine phosphate; Etoposide; Vincristine; Imatinib Mesylate; Daunorubicin; Mercaptopurine; Pegaspargase; Immunosuppressive Agents; Immunologic Factors